Pfizer (PFE) exceeded Street forecasts with its Q3 2025 results on Tuesday, thanks mainly to sales from its COVID vaccine developed with BioNTech (BNTX), and the company raised its full-year earnings outlook while reaffirming the revenue guidance.
However, the New York-based pharma giant indicated a topline contraction of ~6% YoY with $16.7B of revenue as demand for its Paxlovid COVID pill and Comirnaty COVID vaccine continued to decline.
The company reported $1.15B in revenue from Comirnaty, indicating a ~20% YoY fall operationally due to factors such as narrower CDC recommendations but still exceeding the $1.08B projected by analysts, according to Bloomberg data.
Meanwhile, Paxlovid added $1.23B to the topline, missing $1.44B in the consensus, as sales for the antiviral contracted 55% YoY operationally due to reasons including lower COVID-19 infections globally and weaker government procurements.
Pfizer’s (PFE) blood thinner Eliquis, marketed with Bristol Myers (BMY), brought in $2.02B in revenue, and its Prevnar franchise of vaccines added $1.74B compared to the $1.87B and $1.75B projected by analysts, respectively.
While the company reiterated its revenue guidance of $61.0B – $64.0B for 2025, it increased and narrowed its outlook for adjusted earnings to $3.00 – $3.15 per share compared with $2.90 to $3.10 previously and in line with $3.04 in the consensus.
Investors will keep a close eye on CEO Albert Bourla’s comments at the earnings call scheduled for 10:00 AM ET after Pfizer’s (PFE) recent buyout deal with weight loss drugmaker Metsera (MTSR) sparked a bidding war between the company and Novo Nordisk (NVO).